晚期非小细胞肺癌患者血清TGF-β1和VEGF的表达与临床疗效的相关性  

Correlation between the expression of TGF-β1 and VEGF in advanced NSCLC And their clinical efficacy

作　　者：刘永刚[1] 杜晓萍[1] 王剑英[1] 王晓红[1] 

机构地区：[1]包头市肿瘤医院,内蒙古包头014030

出　　处：《疾病监测与控制》2014年第4期210-211,共2页Journal of Diseases Monitor and Control

摘　　要：目的观察探讨晚期非小细胞肺癌患者血清转化生长因子β1(TGF-β1)和血管内皮生长因子(VEGF)的表达与临床疗效的相关性。方法选取2012年我院晚期非小细胞肺癌化疗疗效达临床获益(CR+PR+SD)的患者30例,酶联免疫吸附法(ELISA)检测其治疗前、化疗2周期至4周期后疗效达临床获益时,以及患者疾病进展时血清TGF-β1和VEGF水平。将不同时期的TGF-β1和VEGF水平进行比较。结果患者化疗疗效达临床获益时的血清TGF-β1和VEGF水平较治疗前下降,无统计学差异;在疾病进展时血清TGF-β1和VEGF水平较临床获益时明显增高,有统计学差异。结论晚期非小细胞肺癌患者血清TGF-β1和VEGF的表达与临床疗效相关,可作为患者疗效评价以及疾病监测的指标。Objective To measure serum levels of TGF-β1 and VEGF in patients with advanced non-small cell hang cancer （NSCLC） and determine their clinical efficacy. Methods Serum levels of TGF-β1 and VEGF were determined by＇ELISA in 30 cases of advanced NSCLC, different period serum levels were compared of prior therapy, clinical benefit and progressive disease. Results Serum levels of TGF-β1 and VEGF in patients with the clinical benefit were lower in prior therapy. Serum levels of TGF-β1 and VEGF in patients with progressive disease period were significantly higher than in the clinical benefit. （P〈0.01）. Conclusion Serum levels of TGF-β1 and VEGF in advanced NSCLC patients were positively correlated their clinical efficacy, may be useful in estimating the efficacy and detection the development and for transfer of NSCLC.

关 键 词：非小细胞肺癌 TGF-B1 VEGF 疗效 

分 类 号：R734.2[医药卫生—肿瘤]